News

Company   ImmuPharma PLC
TIDM         IMM
Headline     Interim Results
Released    07:00 25-Sep-08
Number     2638E

FOR IMMEDIATE RELEASE

London, 25 September 2008

Interim results announcement for the six months ended 30 June 2008

ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2008.

INTERIM HIGHLIGHTS

■ First patients dosed in Phase IIb trial of our lead asset for lupus, IPP-201101, during the period under review with subsequent ongoing progress being made and headline efficacy data expected later in the year;

■ Successfully obtained LUPUZOR™ trademark for IPP-201101, our lead asset for lupus

■ Encouraging pre-clinical data from new portfolio candidate, IPP-204106 for multiple forms of cancer

■ Raised £2.7m in a share placing from UK and Swiss institutional investors;

■ In addition to our discovery pipeline, our portfolio now includes five drug candidates:
            □ IPP-201101, LUPUZOR™ for the treatment of lupus
            □ IPP-204106, for the treatment of cancer
            □ IPP-201007, for the treatment of inflammation
            □ IPP-102199, for the treatment of moderate and severe pain
            □ IPP-203101, for the treatment of MRSA and other hospital-
               acquired infections

Commenting on the progress to date and the outlook for ImmuPharma, Dimitri Dimitriou, Chief Executive Officer, said: "The first half of 2008 has been an exciting time for ImmuPharma with the addition of IPP-204106 for the treatment of cancer, the first patients being dosed with LUPUZOR™ and ongoing progress being made in a Phase IIb trial that is anticipated to report headline efficacy data later in the year, and a successful share placement raising £2.7m. The Company continues to develop its assets and discussions with potential partners."

For further information please contact:

ImmuPharma PLC
Dimitri Dimitriou, Chief Executive Officer                         +44 20 7152 4080
Dr Robert Zimmer, President & Chief Scientific Officer      + 33 389 32 7650
Richard Warr, Chairman                                                +44 20 7152 4080

Buchanan Communications +44 20 7466 5000

Lisa Baderoon
Rebecca Skye-Dietrich

Panmure Gordon & Co
NOMAD and Broker +44 20 7459 3600
Andrew Burnett
Ashton Clanfield
Rakesh Sharma

Please click below to view or download the full Interim Results.


Home About ImmuPharma Lead compounds Discovery pipeline Management team News For Investors Contact us	News Company ImmuPharma PLC TIDM IMM Headline Interim Results Released 07:00 25-Sep-08 Number 2638E FOR IMMEDIATE RELEASE London, 25 September 2008 Interim results announcement for the six months ended 30 June 2008 ImmuPharma plc (LSE:IMM), the specialist discovery and development pharmaceutical company is pleased to announce its interim results for the six months ended 30 June 2008. INTERIM HIGHLIGHTS ■ First patients dosed in Phase IIb trial of our lead asset for lupus, IPP-201101, during the period under review with subsequent ongoing progress being made and headline efficacy data expected later in the year; ■ Successfully obtained LUPUZOR™ trademark for IPP-201101, our lead asset for lupus ■ Encouraging pre-clinical data from new portfolio candidate, IPP-204106 for multiple forms of cancer ■ Raised £2.7m in a share placing from UK and Swiss institutional investors; ■ In addition to our discovery pipeline, our portfolio now includes five drug candidates: □ IPP-201101, LUPUZOR™ for the treatment of lupus □ IPP-204106, for the treatment of cancer □ IPP-201007, for the treatment of inflammation □ IPP-102199, for the treatment of moderate and severe pain □ IPP-203101, for the treatment of MRSA and other hospital- acquired infections Commenting on the progress to date and the outlook for ImmuPharma, Dimitri Dimitriou, Chief Executive Officer, said: "The first half of 2008 has been an exciting time for ImmuPharma with the addition of IPP-204106 for the treatment of cancer, the first patients being dosed with LUPUZOR™ and ongoing progress being made in a Phase IIb trial that is anticipated to report headline efficacy data later in the year, and a successful share placement raising £2.7m. The Company continues to develop its assets and discussions with potential partners." For further information please contact: ImmuPharma PLC Dimitri Dimitriou, Chief Executive Officer +44 20 7152 4080 Dr Robert Zimmer, President & Chief Scientific Officer + 33 389 32 7650 Richard Warr, Chairman +44 20 7152 4080 Buchanan Communications +44 20 7466 5000 Lisa Baderoon Rebecca Skye-Dietrich Panmure Gordon & Co NOMAD and Broker +44 20 7459 3600 Andrew Burnett Ashton Clanfield Rakesh Sharma Please click below to view or download the full Interim Results. ©2008 London Stock Exchange plc. All rights reserved